ARTICLE | Strategy
Clinical takeoff for new epigenetic targets
October 17, 2013 7:00 AM UTC
There is little doubt that 2014 will be a banner year for next-generation epigenetics companies, with key clinical data expected for next-generation drugs and first-generation candidates that target new epigenetic regulators. But the big biotech and pharma companies that carved up the space in recent years might have clinical data even sooner, as the American Society of Hematology meeting in December should provide a window into at least two candidates in hematologic
malignancies...